Share Price and Basic Stock Data
Last Updated: November 10, 2025, 1:12 pm
| PEG Ratio | -9.61 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Amrutanjan Health Care Ltd, a prominent player in the pharmaceuticals sector, reported a share price of ₹741 and a market capitalization of ₹2,143 Cr. The company has shown a robust revenue growth trajectory, with sales rising from ₹406 Cr in FY 2022 to ₹421 Cr in FY 2024, and a trailing twelve months (TTM) revenue of ₹462 Cr. Quarterly sales figures demonstrate fluctuations, with a peak of ₹127.06 Cr in Mar 2024, indicating a recovery from a lower sales figure of ₹70.95 Cr in Jun 2022. The company’s operational performance has exhibited resilience, especially in the latest quarters, where sales reached ₹116.99 Cr in Dec 2023 and ₹135.41 Cr in Mar 2025. This growth trajectory can be attributed to a diversified product portfolio and effective market strategies, enabling Amrutanjan to navigate challenges effectively.
Profitability and Efficiency Metrics
Amrutanjan’s profitability metrics reflect a mixed performance, with a reported net profit of ₹55 Cr and a net profit margin of 11.90% as of FY 2025. The operating profit margin (OPM) stood at 8.97%, slightly below the industry average, suggesting room for improvement in operational efficiency. The company’s return on equity (ROE) was reported at 16.5%, while return on capital employed (ROCE) was 22.4%, indicative of effective capital utilization. The interest coverage ratio (ICR) at an impressive 78.72x signifies strong earnings relative to interest expenses, reflecting a solid financial structure. However, the cash conversion cycle (CCC) at -23 days indicates effective management of working capital, allowing for swift cash flow cycles. These metrics highlight Amrutanjan’s ability to maintain profitability while managing costs and operational efficiency.
Balance Sheet Strength and Financial Ratios
The balance sheet of Amrutanjan Health Care Ltd shows a stable financial position, with total reserves reported at ₹324 Cr and minimal borrowings of ₹2 Cr, indicating a low debt-to-equity ratio. The company’s current ratio stands at a healthy 3.46, suggesting strong liquidity and the ability to cover short-term liabilities. The price-to-book value (P/BV) ratio is at 6.85x, which is relatively high compared to typical sector norms, indicating that the stock may be priced at a premium. Furthermore, the total assets increased to ₹421 Cr in FY 2025 from ₹362 Cr in FY 2023, reflecting ongoing investment in growth. The company’s efficiency ratios, particularly the inventory turnover ratio, demonstrate effective inventory management, which is critical for maintaining profitability in the competitive pharmaceutical landscape.
Shareholding Pattern and Investor Confidence
Amrutanjan’s shareholding pattern reveals a diverse ownership structure, with promoters holding 46.52% of the stake, while foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 2.38% and 12.90%, respectively. The public owns 38.16% of the shares, indicating broad market participation. Notably, promoter shareholding has decreased from 50.02% in Dec 2022 to 46.52% in Mar 2025, which may raise concerns about management control. However, the increase in institutional ownership, particularly DIIs, suggests growing investor confidence in the company’s future prospects. The total number of shareholders stood at 47,954 as of Mar 2025, reflecting a strong retail investor interest in the stock, which is pivotal for maintaining market stability and supporting price levels.
Outlook, Risks, and Final Insight
Looking ahead, Amrutanjan Health Care Ltd faces both opportunities and challenges. The company’s ability to sustain revenue growth amidst fluctuating sales indicates a robust operational framework, but it must enhance profitability margins to align with industry standards. Risks include potential market volatility and competitive pressures from both domestic and international players. Additionally, the declining promoter shareholding may signal concerns regarding management’s commitment. Nevertheless, the strong balance sheet, low debt levels, and high interest coverage ratio position the company favorably for future growth. If Amrutanjan can effectively leverage its strengths while addressing identified risks, it has the potential to enhance shareholder value significantly. Strategic initiatives focused on innovation and market expansion could further bolster its competitive stance in the pharmaceuticals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Amrutanjan Health Care Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,611.89 Cr | 1,176.68 | 55.83 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.95 | 110.72 | 97.65 | 100.32 | 77.86 | 99.31 | 116.99 | 127.06 | 83.74 | 109.92 | 122.75 | 135.41 | 94.05 |
| Expenses | 67.62 | 94.79 | 85.49 | 87.34 | 70.71 | 92.47 | 95.42 | 110.82 | 80.19 | 96.32 | 99.40 | 117.71 | 85.61 |
| Operating Profit | 3.33 | 15.93 | 12.16 | 12.98 | 7.15 | 6.84 | 21.57 | 16.24 | 3.55 | 13.60 | 23.35 | 17.70 | 8.44 |
| OPM % | 4.69% | 14.39% | 12.45% | 12.94% | 9.18% | 6.89% | 18.44% | 12.78% | 4.24% | 12.37% | 19.02% | 13.07% | 8.97% |
| Other Income | 3.01 | 3.03 | 3.68 | 4.82 | 3.69 | 3.95 | 3.76 | 4.95 | 4.45 | 4.05 | 4.36 | 4.82 | 4.43 |
| Interest | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 |
| Depreciation | 1.07 | 1.52 | 1.31 | 1.31 | 1.39 | 1.55 | 1.58 | 1.53 | 1.59 | 1.65 | 1.66 | 1.62 | 1.53 |
| Profit before tax | 5.25 | 17.42 | 14.51 | 16.47 | 9.43 | 9.21 | 23.70 | 19.61 | 6.35 | 15.94 | 25.99 | 20.86 | 11.29 |
| Tax % | 30.29% | 26.75% | 26.12% | 22.95% | 25.56% | 25.62% | 26.41% | 30.34% | 27.24% | 25.97% | 25.93% | 27.23% | 26.40% |
| Net Profit | 3.66 | 12.77 | 10.71 | 12.70 | 7.01 | 6.85 | 17.45 | 13.66 | 4.62 | 11.80 | 19.25 | 15.18 | 8.31 |
| EPS in Rs | 1.25 | 4.37 | 3.66 | 4.34 | 2.40 | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 |
Last Updated: August 20, 2025, 1:50 pm
Below is a detailed analysis of the quarterly data for Amrutanjan Health Care Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 94.05 Cr.. The value appears to be declining and may need further review. It has decreased from 135.41 Cr. (Mar 2025) to 94.05 Cr., marking a decrease of 41.36 Cr..
- For Expenses, as of Jun 2025, the value is 85.61 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 117.71 Cr. (Mar 2025) to 85.61 Cr., marking a decrease of 32.10 Cr..
- For Operating Profit, as of Jun 2025, the value is 8.44 Cr.. The value appears to be declining and may need further review. It has decreased from 17.70 Cr. (Mar 2025) to 8.44 Cr., marking a decrease of 9.26 Cr..
- For OPM %, as of Jun 2025, the value is 8.97%. The value appears to be declining and may need further review. It has decreased from 13.07% (Mar 2025) to 8.97%, marking a decrease of 4.10%.
- For Other Income, as of Jun 2025, the value is 4.43 Cr.. The value appears to be declining and may need further review. It has decreased from 4.82 Cr. (Mar 2025) to 4.43 Cr., marking a decrease of 0.39 Cr..
- For Interest, as of Jun 2025, the value is 0.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.04 Cr. (Mar 2025) to 0.05 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Jun 2025, the value is 1.53 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.62 Cr. (Mar 2025) to 1.53 Cr., marking a decrease of 0.09 Cr..
- For Profit before tax, as of Jun 2025, the value is 11.29 Cr.. The value appears to be declining and may need further review. It has decreased from 20.86 Cr. (Mar 2025) to 11.29 Cr., marking a decrease of 9.57 Cr..
- For Tax %, as of Jun 2025, the value is 26.40%. The value appears to be improving (decreasing) as expected. It has decreased from 27.23% (Mar 2025) to 26.40%, marking a decrease of 0.83%.
- For Net Profit, as of Jun 2025, the value is 8.31 Cr.. The value appears to be declining and may need further review. It has decreased from 15.18 Cr. (Mar 2025) to 8.31 Cr., marking a decrease of 6.87 Cr..
- For EPS in Rs, as of Jun 2025, the value is 2.87. The value appears to be declining and may need further review. It has decreased from 5.25 (Mar 2025) to 2.87, marking a decrease of 2.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:22 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 131 | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 462 |
| Expenses | 108 | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 399 |
| Operating Profit | 23 | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 63 |
| OPM % | 18% | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 14% |
| Other Income | 3 | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 18 |
| Interest | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 |
| Profit before tax | 21 | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 74 |
| Tax % | 32% | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | |
| Net Profit | 15 | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 55 |
| EPS in Rs | 4.97 | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 18.86 |
| Dividend Payout % | 32% | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 13.33% | 29.41% | 0.00% | -9.09% | 25.00% | 0.00% | 144.00% | 9.84% | -40.30% | 12.50% | 13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 16.08% | -29.41% | -9.09% | 34.09% | -25.00% | 144.00% | -134.16% | -50.13% | 52.80% | 0.83% |
Amrutanjan Health Care Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 12% |
| 3 Years: | 4% |
| TTM: | 8% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 15% |
| 3 Years: | -9% |
| TTM: | 28% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | -1% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 20% |
| 3 Years: | 15% |
| Last Year: | 17% |
Last Updated: September 4, 2025, 11:10 pm
Balance Sheet
Last Updated: June 16, 2025, 12:30 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 94 | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 |
| Borrowings | 6 | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 |
| Other Liabilities | 22 | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 |
| Total Liabilities | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 |
| Fixed Assets | 15 | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 |
| CWIP | 1 | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 |
| Investments | 14 | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 |
| Other Assets | 95 | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 |
| Total Assets | 124 | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 |
Below is a detailed analysis of the balance sheet data for Amrutanjan Health Care Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 3.00 Cr..
- For Reserves, as of Mar 2025, the value is 324.00 Cr.. The value appears strong and on an upward trend. It has increased from 286.00 Cr. (Mar 2024) to 324.00 Cr., marking an increase of 38.00 Cr..
- For Borrowings, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 93.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 77.00 Cr. (Mar 2024) to 93.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 421.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 367.00 Cr. (Mar 2024) to 421.00 Cr., marking an increase of 54.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 49.00 Cr.. The value appears to be declining and may need further review. It has decreased from 50.00 Cr. (Mar 2024) to 49.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Mar 2024) to 16.00 Cr., marking an increase of 14.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 356.00 Cr.. The value appears strong and on an upward trend. It has increased from 315.00 Cr. (Mar 2024) to 356.00 Cr., marking an increase of 41.00 Cr..
- For Total Assets, as of Mar 2025, the value is 421.00 Cr.. The value appears strong and on an upward trend. It has increased from 367.00 Cr. (Mar 2024) to 421.00 Cr., marking an increase of 54.00 Cr..
Notably, the Reserves (324.00 Cr.) exceed the Borrowings (2.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 17.00 | 25.00 | 32.00 | 27.00 | 28.00 | 31.00 | 29.00 | 74.00 | 79.00 | 44.00 | 50.00 | 56.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 66 | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 |
| Inventory Days | 45 | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 |
| Days Payable | 44 | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 |
| Cash Conversion Cycle | 67 | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 | -5 | -23 |
| Working Capital Days | 39 | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 |
| ROCE % | 24% | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 1,466,269 | 0.69 | 110.79 | 1,466,269 | 2025-04-22 15:57:00 | 0% |
| Sundaram Small Cap Fund | 484,538 | 1.07 | 36.61 | 484,538 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential FMCG Fund - Dividend | 34,772 | 0.15 | 2.63 | 34,772 | 2025-04-22 15:57:00 | 0% |
| ICICI Prudential FMCG Fund - Growth | 34,772 | 0.15 | 2.63 | 34,772 | 2025-04-22 15:57:00 | 0% |
Key Financial Ratios
| Month | Mar 17 | Mar 16 | Mar 15 | Mar 14 | Mar 13 |
|---|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Diluted EPS (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| Cash EPS (Rs.) | 16.43 | 16.37 | 12.51 | 10.98 | 9.47 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 86.22 | 74.40 | 64.97 | 61.06 | 56.29 |
| Revenue From Operations / Share (Rs.) | 153.25 | 127.77 | 113.97 | 96.97 | 94.18 |
| PBDIT / Share (Rs.) | 23.16 | 24.95 | 19.32 | 16.93 | 14.83 |
| PBIT / Share (Rs.) | 21.20 | 22.66 | 17.13 | 14.47 | 12.28 |
| PBT / Share (Rs.) | 22.75 | 22.36 | 16.64 | 13.26 | 10.59 |
| Net Profit / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| NP After MI And SOA / Share (Rs.) | 14.47 | 14.08 | 10.31 | 8.51 | 6.92 |
| PBDIT Margin (%) | 15.11 | 19.52 | 16.95 | 17.46 | 15.75 |
| PBIT Margin (%) | 13.83 | 17.73 | 15.02 | 14.92 | 13.04 |
| PBT Margin (%) | 14.84 | 17.50 | 14.60 | 13.67 | 11.24 |
| Net Profit Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| NP After MI And SOA Margin (%) | 9.43 | 11.01 | 9.04 | 8.78 | 7.34 |
| Return on Networth / Equity (%) | 16.77 | 18.92 | 15.87 | 13.94 | 12.29 |
| Return on Capital Employeed (%) | 23.87 | 29.45 | 25.52 | 22.73 | 20.83 |
| Return On Assets (%) | 13.07 | 14.65 | 12.16 | 10.34 | 8.14 |
| Total Debt / Equity (X) | 0.01 | 0.02 | 0.02 | 0.08 | 0.18 |
| Asset Turnover Ratio (%) | 1.48 | 1.35 | 1.30 | 1.12 | 1.00 |
| Current Ratio (X) | 3.46 | 3.59 | 3.20 | 2.87 | 1.67 |
| Quick Ratio (X) | 3.15 | 3.27 | 2.87 | 2.55 | 1.40 |
| Inventory Turnover Ratio (X) | 7.67 | 7.09 | 6.93 | 6.06 | 5.44 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 27.34 | 33.93 | 37.58 | 43.33 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 23.52 | 27.97 | 29.14 | 31.67 |
| Earning Retention Ratio (%) | 0.00 | 72.66 | 66.07 | 62.42 | 56.67 |
| Cash Earning Retention Ratio (%) | 0.00 | 76.48 | 72.03 | 70.86 | 68.33 |
| Interest Coverage Ratio (X) | 78.72 | 83.47 | 39.72 | 14.01 | 8.75 |
| Interest Coverage Ratio (Post Tax) (X) | 43.91 | 48.10 | 22.20 | 8.05 | 5.08 |
| Enterprise Value (Cr.) | 817.64 | 564.15 | 663.81 | 156.21 | 169.76 |
| EV / Net Operating Revenue (X) | 3.65 | 3.02 | 3.99 | 1.10 | 1.23 |
| EV / EBITDA (X) | 24.16 | 15.47 | 23.51 | 6.31 | 7.83 |
| MarketCap / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| Retention Ratios (%) | 0.00 | 72.65 | 66.06 | 62.41 | 56.66 |
| Price / BV (X) | 6.85 | 5.61 | 7.36 | 2.06 | 2.06 |
| Price / Net Operating Revenue (X) | 3.85 | 3.27 | 4.20 | 1.29 | 1.23 |
| EarningsYield | 0.02 | 0.03 | 0.02 | 0.06 | 0.05 |
After reviewing the key financial ratios for Amrutanjan Health Care Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 17, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 16) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Diluted EPS (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For Cash EPS (Rs.), as of Mar 17, the value is 16.43. This value is within the healthy range. It has increased from 16.37 (Mar 16) to 16.43, marking an increase of 0.06.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 17, the value is 86.22. It has increased from 74.40 (Mar 16) to 86.22, marking an increase of 11.82.
- For Revenue From Operations / Share (Rs.), as of Mar 17, the value is 153.25. It has increased from 127.77 (Mar 16) to 153.25, marking an increase of 25.48.
- For PBDIT / Share (Rs.), as of Mar 17, the value is 23.16. This value is within the healthy range. It has decreased from 24.95 (Mar 16) to 23.16, marking a decrease of 1.79.
- For PBIT / Share (Rs.), as of Mar 17, the value is 21.20. This value is within the healthy range. It has decreased from 22.66 (Mar 16) to 21.20, marking a decrease of 1.46.
- For PBT / Share (Rs.), as of Mar 17, the value is 22.75. This value is within the healthy range. It has increased from 22.36 (Mar 16) to 22.75, marking an increase of 0.39.
- For Net Profit / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For NP After MI And SOA / Share (Rs.), as of Mar 17, the value is 14.47. This value is within the healthy range. It has increased from 14.08 (Mar 16) to 14.47, marking an increase of 0.39.
- For PBDIT Margin (%), as of Mar 17, the value is 15.11. This value is within the healthy range. It has decreased from 19.52 (Mar 16) to 15.11, marking a decrease of 4.41.
- For PBIT Margin (%), as of Mar 17, the value is 13.83. This value is within the healthy range. It has decreased from 17.73 (Mar 16) to 13.83, marking a decrease of 3.90.
- For PBT Margin (%), as of Mar 17, the value is 14.84. This value is within the healthy range. It has decreased from 17.50 (Mar 16) to 14.84, marking a decrease of 2.66.
- For Net Profit Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For NP After MI And SOA Margin (%), as of Mar 17, the value is 9.43. This value is within the healthy range. It has decreased from 11.01 (Mar 16) to 9.43, marking a decrease of 1.58.
- For Return on Networth / Equity (%), as of Mar 17, the value is 16.77. This value is within the healthy range. It has decreased from 18.92 (Mar 16) to 16.77, marking a decrease of 2.15.
- For Return on Capital Employeed (%), as of Mar 17, the value is 23.87. This value is within the healthy range. It has decreased from 29.45 (Mar 16) to 23.87, marking a decrease of 5.58.
- For Return On Assets (%), as of Mar 17, the value is 13.07. This value is within the healthy range. It has decreased from 14.65 (Mar 16) to 13.07, marking a decrease of 1.58.
- For Total Debt / Equity (X), as of Mar 17, the value is 0.01. This value is within the healthy range. It has decreased from 0.02 (Mar 16) to 0.01, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 17, the value is 1.48. It has increased from 1.35 (Mar 16) to 1.48, marking an increase of 0.13.
- For Current Ratio (X), as of Mar 17, the value is 3.46. This value exceeds the healthy maximum of 3. It has decreased from 3.59 (Mar 16) to 3.46, marking a decrease of 0.13.
- For Quick Ratio (X), as of Mar 17, the value is 3.15. This value exceeds the healthy maximum of 2. It has decreased from 3.27 (Mar 16) to 3.15, marking a decrease of 0.12.
- For Inventory Turnover Ratio (X), as of Mar 17, the value is 7.67. This value is within the healthy range. It has increased from 7.09 (Mar 16) to 7.67, marking an increase of 0.58.
- For Dividend Payout Ratio (NP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 27.34 (Mar 16) to 0.00, marking a decrease of 27.34.
- For Dividend Payout Ratio (CP) (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 23.52 (Mar 16) to 0.00, marking a decrease of 23.52.
- For Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 72.66 (Mar 16) to 0.00, marking a decrease of 72.66.
- For Cash Earning Retention Ratio (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 76.48 (Mar 16) to 0.00, marking a decrease of 76.48.
- For Interest Coverage Ratio (X), as of Mar 17, the value is 78.72. This value is within the healthy range. It has decreased from 83.47 (Mar 16) to 78.72, marking a decrease of 4.75.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 17, the value is 43.91. This value is within the healthy range. It has decreased from 48.10 (Mar 16) to 43.91, marking a decrease of 4.19.
- For Enterprise Value (Cr.), as of Mar 17, the value is 817.64. It has increased from 564.15 (Mar 16) to 817.64, marking an increase of 253.49.
- For EV / Net Operating Revenue (X), as of Mar 17, the value is 3.65. This value exceeds the healthy maximum of 3. It has increased from 3.02 (Mar 16) to 3.65, marking an increase of 0.63.
- For EV / EBITDA (X), as of Mar 17, the value is 24.16. This value exceeds the healthy maximum of 15. It has increased from 15.47 (Mar 16) to 24.16, marking an increase of 8.69.
- For MarketCap / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For Retention Ratios (%), as of Mar 17, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 72.65 (Mar 16) to 0.00, marking a decrease of 72.65.
- For Price / BV (X), as of Mar 17, the value is 6.85. This value exceeds the healthy maximum of 3. It has increased from 5.61 (Mar 16) to 6.85, marking an increase of 1.24.
- For Price / Net Operating Revenue (X), as of Mar 17, the value is 3.85. This value exceeds the healthy maximum of 3. It has increased from 3.27 (Mar 16) to 3.85, marking an increase of 0.58.
- For EarningsYield, as of Mar 17, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 16) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Amrutanjan Health Care Ltd:
- Net Profit Margin: 9.43%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 23.87% (Industry Average ROCE: 16.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.77% (Industry Average ROE: 14.47%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 43.91
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3.15
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.3 (Industry average Stock P/E: 46.82)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.43%
FAQ
What is the intrinsic value of Amrutanjan Health Care Ltd?
Amrutanjan Health Care Ltd's intrinsic value (as of 10 November 2025) is 559.93 which is 20.35% lower the current market price of 703.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 2,034 Cr. market cap, FY2025-2026 high/low of 843/544, reserves of ₹324 Cr, and liabilities of 421 Cr.
What is the Market Cap of Amrutanjan Health Care Ltd?
The Market Cap of Amrutanjan Health Care Ltd is 2,034 Cr..
What is the current Stock Price of Amrutanjan Health Care Ltd as on 10 November 2025?
The current stock price of Amrutanjan Health Care Ltd as on 10 November 2025 is 703.
What is the High / Low of Amrutanjan Health Care Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Amrutanjan Health Care Ltd stocks is 843/544.
What is the Stock P/E of Amrutanjan Health Care Ltd?
The Stock P/E of Amrutanjan Health Care Ltd is 37.3.
What is the Book Value of Amrutanjan Health Care Ltd?
The Book Value of Amrutanjan Health Care Ltd is 113.
What is the Dividend Yield of Amrutanjan Health Care Ltd?
The Dividend Yield of Amrutanjan Health Care Ltd is 0.64 %.
What is the ROCE of Amrutanjan Health Care Ltd?
The ROCE of Amrutanjan Health Care Ltd is 22.4 %.
What is the ROE of Amrutanjan Health Care Ltd?
The ROE of Amrutanjan Health Care Ltd is 16.5 %.
What is the Face Value of Amrutanjan Health Care Ltd?
The Face Value of Amrutanjan Health Care Ltd is 1.00.